Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI

Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and phosphorylation of downstream substrates including phosph...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolson, Phillip L.R., Hughes, Craig E., Watson, Stephanie, Nock, Sophie H., Hardy, Alexander T., Watson, Callum N., Montague, Samantha J., Clifford, Hayley, Huissoon, Aarnoud P., Malcor, Jean-Daniel, Thomas, Mark R., Pollitt, Alice Y., Tomlinson, Michael G., Pratt, Guy, Watson, Steve P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269309/
https://www.ncbi.nlm.nih.gov/pubmed/30026342
http://dx.doi.org/10.3324/haematol.2018.193391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269309/
https://www.ncbi.nlm.nih.gov/pubmed/30026342
http://dx.doi.org/10.3324/haematol.2018.193391

Ejemplares similares